Reduction of Visceral Adipose Tissue and Improvement of Metabolic Indices: Effect of Dexfenfluramine in NIDDM
| Autor: | Sharon Marks, Niall Moore, Mo L. Clark, T. Derek R. Hockaday, Boyd Jg Strauss |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Calorie Endocrinology Diabetes and Metabolism Medicine (miscellaneous) Adipose tissue Body Mass Index Impaired glucose tolerance chemistry.chemical_compound Endocrinology Internal medicine Diabetes mellitus Appetite Depressants Fenfluramine medicine Humans Insulin Obesity Triglycerides medicine.diagnostic_test Triglyceride business.industry Public Health Environmental and Occupational Health Magnetic resonance imaging Middle Aged Dexfenfluramine medicine.disease Magnetic Resonance Imaging Diet Cholesterol Adipose Tissue Diabetes Mellitus Type 2 chemistry Body Composition Body Constitution Energy Intake business Body mass index Food Science medicine.drug |
| Zdroj: | Obesity Research. 4:1-7 |
| ISSN: | 1071-7323 |
| DOI: | 10.1002/j.1550-8528.1996.tb00506.x |
| Popis: | Increased visceral adipose tissue is thought to contribute to impaired glucose tolerance. We studied 10 men with non-insulin dependent diabetes (NIDDM) before and after a 12-week intervention study using dexfenfluramine. Subjects had a mean body mass index (BMI) of 26.4 +/- 1.7 kg/m2 and had an abdominal distribution of body fatness (waist-to hip ratio > 0.9). Anthropometric indices, biochemistry, macronutrient intake from 7-day food records as well as a euglycaemic glucose clamp and magnetic resonance imaging (MRI) were performed at week 0 and week 12. Abdominal adipose tissue area measured by MRI was reduced from 854 +/- 270 cm2 to 666 +/- 231 cm2 (p = 0.003) due mainly to a selective 32% reduction in visceral fat area from 484 +/- 230 cm2 to 333 +/- 72 cm2 (p = 0.002). Insulin sensitivity improved from 0.29 +/- 0.13 [min-1 (mU/L)] to 0.54 +/- 0.21 [min-1 (mU/L)] (p = 0.01) and C-peptide levels reduced from 0.77 +/- 0.24 mumol/L to 0.58 +/- 0.15 mumol/L (p = 0.002). The reductions in fasting glucose and glycated haemoglobin failed to achieve significance. Fasting total cholesterol and triglyceride levels significantly reduced (p = < 0.001 and p = 0.021 respectively). There was a reduction in total energy intake (p = 0.005) due to a significant reduction in calories obtained from fat (p < 0.001). Thus dexfenfluramine was shown to be a useful adjunct therapy for the reduction of visceral fat in abdominally-obese men with NIDDM with an associated improvement in insulin sensitivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text